Bright Minds Biosciences Stock Current Asset
| DRUG Stock | USD 33.75 1.07 3.07% |
Fundamental analysis of Bright Minds allows traders to better anticipate movements in Bright Minds' stock price by examining its financial health and performance throughout various phases of its business cycle.
The Bright Minds' current Total Current Assets is estimated to increase to about 8.4 M, while Non Current Assets Total are projected to decrease to roughly 75.3 K. Bright | Current Asset | Build AI portfolio with Bright Stock |
Bright Minds Biosciences Company Current Asset Analysis
Bright Minds' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Bright Current Asset Historical Pattern
Today, most investors in Bright Minds Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bright Minds' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bright Minds current asset as a starting point in their analysis.
Bright Minds Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Bright Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Bright Minds Biosciences has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Bright Minds Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bright Minds from analyzing Bright Minds' financial statements. These drivers represent accounts that assess Bright Minds' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bright Minds' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 53.9M | 61.4M | 9.5M | 734.8K | 845.0K | 802.8K |
Bright Minds ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.Environmental | Governance | Social |
Bright Fundamentals
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 196.79 M | ||||
| Shares Outstanding | 7.08 M | ||||
| Shares Owned By Insiders | 22.54 % | ||||
| Shares Owned By Institutions | 74.81 % | ||||
| Number Of Shares Shorted | 169.04 K | ||||
| Price To Book | 5.89 X | ||||
| EBITDA | (7.28 M) | ||||
| Net Income | (2.8 M) | ||||
| Cash And Equivalents | 8.64 M | ||||
| Cash Per Share | 0.71 X | ||||
| Total Debt | 118.96 K | ||||
| Current Ratio | 22.88 X | ||||
| Book Value Per Share | 7.87 X | ||||
| Cash Flow From Operations | (1.85 M) | ||||
| Short Ratio | 2.74 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Target Price | 93.89 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 239.06 M | ||||
| Total Asset | 6.1 M | ||||
| Retained Earnings | (34.35 M) | ||||
| Working Capital | 5.46 M | ||||
| Net Asset | 6.1 M |
About Bright Minds Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Bright Minds Piotroski F Score and Bright Minds Altman Z Score analysis. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.